GCPII Imaging and Cancer

Title: GCPII Imaging and Cancer

Volume: 19 Issue: 9

Author(s): C. A. Foss, R. C. Mease, S. Y. Cho, H. J. Kim and M. G. Pomper

Affiliation:

Keywords: Prostate-specific membrane antigen, PSMA, prostate cancer, molecular imaging, PET, SPECT, Glutamate carboxypeptidase II, malignancies, enzymatic activity, heterogeneous expression

Abstract: Glutamate carboxypeptidase II (GCPII) in the central nervous system is referred to as the prostate-specific membrane antigen (PSMA) in the periphery. PSMA serves as a target for imaging and treatment of prostate cancer and because of its expression in solid tumor neovasculature has the potential to be used in this regard for other malignancies as well. An overview of GCPII/PSMA in cancer, as well as a discussion of imaging and therapy of prostate cancer using a wide variety of PSMA-targeting agents is provided.

Cite this article as:

A. Foss C., C. Mease R., Y. Cho S., J. Kim H. and G. Pomper M., GCPII Imaging and Cancer, Current Medicinal Chemistry 2012; 19 (9) . https://dx.doi.org/10.2174/092986712799462612